• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

87.71 -2.49 (-2.76%)
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,104,249
Open 90.14
Bid (Size) 87.60 (100)
Ask (Size) 92.00 (200)
Prev. Close 90.20
Today's Range 87.36 - 90.14
52wk Range 79.52 - 124.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy? ↗
Today 14:52 EDT
It has been a volatile year for the biotech. 
Via The Motley Fool
News headline image
Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline ↗
October 17, 2026
BioNTech has billions in cash, and its oncology programs are moving into late-stage clinical trials. 
Via The Motley Fool

Performance

52-Week Range 29.3% below 52-week high
87.71
79.5252W Low 124.0052W High
1 Week 11.0% below 1-week high
87.361W Low 98.601W High

BioNTech SE - American Depositary Shares (BNTX) traded between $79.52 and $124.00 over the past 52 weeks and last traded at $87.71, 29.3% below its 52-week high. Over the past week it ranged between $87.36 and $98.60.

Past 12 Months
-8.5%
-8.7%
-4.8%
-16.6%
-9.3%
-18.7%
1W -$8.13
1M -$8.35
3M -$4.45
6M -$17.48
YTD -$8.98
1Y -$20.24

BNTX was -18.7% over the past year, -16.6% over six months, -9.3% year to date, -8.5% in the last week.

12 Months vs Market
BNTX
-18.7%
DIA
+11.2%
SPY
+13.7%
QQQ
+16.1%
IWM
+9.0%

Over the past 12 months BNTX returned -18.7% versus DIA (Dow) +11.2%, SPY (S&P 500) +13.7%, QQQ (Nasdaq 100) +16.1% and IWM (Russell 2000) +9.0%.

Volume & Liquidity 0.91× 3-mo avg
Today 1,104,249 3-mo avg 1.2M
1W
1.3M
1M
1.0M
3M
1.2M
6M
1.1M
YTD
1.1M
1Y
1.1M

BNTX most recently traded 1,104,249 shares against a 3-month average daily volume of 1.2M.

More News

Read More
News headline image
BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer
October 13, 2026
From BioNTech SE
Via GlobeNewswire
News headline image
Moderna Is Now Worth More Than 3X as Much as BioNTech. Which Biotech Stock Is the Smarter Pick? ↗
October 13, 2026
Via The Motley Fool
News headline image
BioNTech Has More Cancer Drugs in Late-Stage Trials Than Most Investors Realize. Is It a Buy Under $100? ↗
October 08, 2026
Via The Motley Fool
News headline image
Bristol Myers Squibb Now Trades at Only 9.4X Forward Earnings -- Is This Value Stock a Buy? ↗
October 03, 2026
Via The Motley Fool
Topics Intellectual Property
News headline image
Moderna vs. BioNTech: Which mRNA Cancer Stock Has More Upside? ↗
September 28, 2026
Via The Motley Fool
News headline image
Which Is the Bigger Story for BioNTech -- Its Colorectal Cancer Vaccine Setback or the Lung Cancer Clinical Success? ↗
September 22, 2026
Via The Motley Fool
News headline image
BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline? ↗
September 22, 2026
Via The Motley Fool
News headline image
BioNTech Threw in the Towel on Its Colorectal Cancer Vaccine Trial. Should Investors Be Worried? ↗
September 18, 2026
Via The Motley Fool
News headline image
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
September 15, 2026
Via FinancialNewsMedia
News headline image
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
September 15, 2026
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
September 14, 2026
From BioNTech SE
Via GlobeNewswire
News headline image
Why Pfizer Stock Was so Healthy in August ↗
September 08, 2026
Via The Motley Fool
Topics Intellectual Property
News headline image
BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now? ↗
September 03, 2026
Via The Motley Fool
News headline image
Is BioNTech Stock a No-Brainer Buy on the Dip? ↗
September 02, 2026
Via The Motley Fool
News headline image
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
August 27, 2026
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
August 27, 2026
From BioNTech SE
Via GlobeNewswire
News headline image
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
August 26, 2026
Via FinancialNewsMedia
News headline image
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
August 26, 2026
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026
August 20, 2026
From BioNTech SE
Via GlobeNewswire
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
August 19, 2026
Via Chartmill
News headline image
BioNTech Just Named a New CEO. Here's What Guido Oelkers' Appointment Means for the Stock. ↗
August 13, 2026
Via The Motley Fool
News headline image
BioNTech (BNTX) Q2 2026 Earnings Call Transcript ↗
August 11, 2026
Via The Motley Fool
Topics Earnings
News headline image
BioNTech Q2 Earnings Call Highlights ↗
August 04, 2026
Via MarketBeat
Topics Earnings

Frequently Asked Questions

Is BioNTech SE - American Depositary Shares publicly traded?
Yes, BioNTech SE - American Depositary Shares is publicly traded.
What exchange does BioNTech SE - American Depositary Shares trade on?
BioNTech SE - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for BioNTech SE - American Depositary Shares?
The ticker symbol for BioNTech SE - American Depositary Shares is BNTX on the Nasdaq Stock Market
What is the current price of BioNTech SE - American Depositary Shares?
The current price of BioNTech SE - American Depositary Shares is 87.71
When was BioNTech SE - American Depositary Shares last traded?
The last trade of BioNTech SE - American Depositary Shares was at 10/16/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap